The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 21, 2016
Filed:
Apr. 19, 2010
Applicant:
John Daniel Dobak, La Jolla, CA (US);
Inventor:
John Daniel Dobak, La Jolla, CA (US);
Assignee:
NEOTHETICS, INC., San Diego, CA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A01N 45/00 (2006.01); A61K 31/56 (2006.01); A01N 43/40 (2006.01); A61K 31/445 (2006.01); A01N 37/18 (2006.01); A61K 31/16 (2006.01); A01N 33/02 (2006.01); A61K 31/135 (2006.01); A61K 31/138 (2006.01); A61K 9/00 (2006.01); A61K 31/573 (2006.01); A61K 47/10 (2006.01); A61K 47/14 (2006.01); A61K 47/34 (2006.01); A61K 47/36 (2006.01); A61K 31/167 (2006.01); A61K 31/4535 (2006.01); A61K 31/567 (2006.01); A61K 31/58 (2006.01); A61K 31/195 (2006.01); A61K 9/50 (2006.01);
U.S. Cl.
CPC ...
A61K 31/138 (2013.01); A61K 9/0014 (2013.01); A61K 9/0019 (2013.01); A61K 9/0021 (2013.01); A61K 31/167 (2013.01); A61K 31/195 (2013.01); A61K 31/4535 (2013.01); A61K 31/567 (2013.01); A61K 31/573 (2013.01); A61K 31/58 (2013.01); A61K 47/10 (2013.01); A61K 47/14 (2013.01); A61K 47/34 (2013.01); A61K 47/36 (2013.01); A61K 9/5031 (2013.01);
Abstract
Compositions, formulations, methods, and systems for treating regional fat deposits comprise contacting a targeted fat deposit with a composition comprising long acting beta-2 adrenergic receptor agonist and a compound that reduces desensitization of the target tissue to the long acting beta-2 adrenergic receptor agonist, for example, glucocorticosteroids and/or ketotifen. Embodiments of the composition are administered, for example, by injection, and/or transdermally.